Summit Global Investments Acquires Shares of 20,609 Guardant Health, Inc. (NASDAQ:GH)

Summit Global Investments acquired a new stake in Guardant Health, Inc. (NASDAQ:GH) in the fourth quarter, HoldingsChannel.com reports. The firm acquired 20,609 shares of the company’s stock, valued at approximately $630,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. R Squared Ltd purchased a new stake in Guardant Health in the 4th quarter valued at $26,000. SBI Securities Co. Ltd. purchased a new stake in shares of Guardant Health in the fourth quarter valued at about $43,000. Kimelman & Baird LLC purchased a new stake in shares of Guardant Health in the fourth quarter valued at about $58,000. Jones Financial Companies Lllp raised its holdings in shares of Guardant Health by 43.5% in the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company’s stock valued at $82,000 after buying an additional 817 shares during the last quarter. Finally, Van ECK Associates Corp raised its holdings in shares of Guardant Health by 47.4% in the fourth quarter. Van ECK Associates Corp now owns 2,887 shares of the company’s stock valued at $88,000 after buying an additional 929 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Stock Up 3.1 %

Shares of GH stock opened at $46.10 on Monday. The business has a fifty day simple moving average of $43.85 and a 200-day simple moving average of $33.63. Guardant Health, Inc. has a fifty-two week low of $15.81 and a fifty-two week high of $50.89. The stock has a market cap of $5.69 billion, a P/E ratio of -12.95 and a beta of 1.50.

Guardant Health (NASDAQ:GH) last posted its earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The business had revenue of $201.81 million for the quarter, compared to analysts’ expectations of $192.50 million. On average, sell-side analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have commented on GH. Stifel Nicolaus upped their price objective on Guardant Health from $45.00 to $53.00 and gave the company a “buy” rating in a research note on Friday, February 21st. The Goldman Sachs Group upped their price target on Guardant Health from $49.00 to $56.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Raymond James restated an “outperform” rating and set a $59.00 price objective (up previously from $39.00) on shares of Guardant Health in a research report on Friday, February 21st. Scotiabank upped their price objective on shares of Guardant Health from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a research report on Monday, February 24th. Finally, JPMorgan Chase & Co. increased their price target on shares of Guardant Health from $50.00 to $55.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. Twenty equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $48.40.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.